Detalhe da pesquisa
1.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029306
2.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753727
3.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Lancet
; 390(10109): 2266-2277, 2017 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916371
4.
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Lancet Oncol
; 13(3): 247-55, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22341744
5.
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Clin Cancer Res
; 27(19): 5258-5271, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301751
6.
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
ESMO Open
; 5(1)2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31958290
7.
PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
J Thorac Oncol
; 9(2): 205-13, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24419418
8.
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
J Clin Oncol
; 31(23): 2895-902, 2013 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23835707